Global BioLife initiates advanced research of a new universal therapeutic drug platform
By Digital News Asia June 5, 2017
- Linebacker is aimed at combating a range of diseases including Alzheimer’s, diabetes and cancer
- It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria
SINGAPORE eDevelopment Limited (SeD), through its subsidiary, Global BioLife Inc (Global BioLife) has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer’s, diabetes and cancer.
The research will be led by two-time Nobel Prize nominee, Daryl Thompson (pic).
Singapore Exchange-listed SeD said Thompson will leverage on his expertise in organic and carbohydrate chemistry and the use of pandemic technology in combatting the Ebola virus in the research and development of this universal therapeutic drug platform, known as Linebacker.
Unlike the traditional approach to cure individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough option for multiple diseases to be cured. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.
Thompson will lead the research to be conducted by Global BioLife in his capacity as director of Scientific Initiatives. Global BioLife is an 80%-held subsidiary of SeD’s wholly-owned subsidiary, Global BioMedical Inc. The remaining stake of Global BioLife is held in equal proportions by Thompson’s GRDG Sciences LLC and Australia Securities Exchange-listed Holista CollTech Limited.
Thompson was nominated for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his expertise to initiate research regarding universal therapeutics to cure the world’s deadliest diseases.
Scott Truesdell, research coordinator and special projects leader at Global BioLife, will execute the research on the Linebacker platform.
Global BioLife has engaged New York Exchange-listed Charles River International Laboratories International, Inc (Charles River) which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
Thompson said: “We expect to obtain validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be completed within twelve months. We have a unique patented technology and are already getting interest from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available.”
“Global BioLife recognises the need for affordable cures to emerging pandemics and we will leverage the team’s deep expertise to develop this new universal therapeutic drug platform”, said Dr Tang Peihong, Global BioLife’s director and chief executive officer. Dr Tang has a Ph.D. in Chemical Engineering and was selected as National Distinguished Expert in China’s Thousand Talents Plan in 2012.
GRDG Sciences LLC is a natural products discovery drug research company formed in Florida, USA, by Mr Daryl Thompson, a natural products scientist. GRDG Sciences LLC works with multiple global institutions such as Charles River.
Holista CollTech Limited is a research-driven biotech company, that resulted from the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. It is dedicated to delivering first-class natural ingredients and wellness products.